December 3, 2019 10:54 AM ESTUpdated 11:14 AM
News Briefing

Ab­b­Vie picks first Alzheimer's, Parkin­son's tar­gets in Mis­sion pact; Amarin files for Vas­cepa OK in Eu­rope

Kathy Wong

Editor

→ Back in 2018, Ab­b­Vie teamed up with pro­tein degra­da­tion ex­perts at Mis­sion Ther­a­peu­tics to fo­cus on deu­biq­ui­ty­lat­ing en­zymes, or DUBs, to tack­le Alzheimer’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times